Resolution of mycobacterium abscessus disease following initiation of elexacaftor/tezacaftor/ ivacaftor

被引：0
|
作者：
Gavey, R. [1 ]
Moore, V [2 ]
Nolan, J. [2 ]
Reid, D. [2 ]
Brown, J. [1 ]
机构：
[1] Cairns Hosp & Hlth Serv, Dept Thorac & Sleep Med, Cairns, Australia
[2] Prince Charles Hosp, Dept Thorac Med, Adult Cyst Fibrosis Ctr, Chermside, Australia
来源：
RESPIROLOGY | 2024年 / 29卷
关键词：
Cystic fibrosis; Nontuberculous mycobacterium; Mycobacterium abscessus; Elexacaftor/Tezacaftor/; Ivacaftor;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
TP074
引用
收藏
页码：162 / 162
页数：1
相关论文
共 50 条
  • [31] Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
    Andrea Gramegna
    Fabio Majo
    Gianfranco Alicandro
    Gloria Leonardi
    Luca Cristiani
    Francesco Amati
    Martina Contarini
    Stefano Aliberti
    Alessandro Giovanni Fiocchi
    Francesco Blasi
    Respiratory Research, 24
  • [32] Acute cholecystitis in cystic fibrosis patients after initiation of treatment with elexacaftor/tezacaftor/ivacaftor
    Garcia, Marta Solis
    Carbajal, Claudia Madrid
    Moreno, Rosa Maria Giron
    MEDICINA CLINICA, 2023, 160 (11): : E5 - E6
  • [33] Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort
    Bacon, Daniel R.
    Stapleton, Amanda
    Goralski, Jennifer L.
    Ebert, Charles S., Jr.
    Thorp, Brian D.
    Nouraie, Mehdi
    Shaffer, Amber D.
    Senior, Brent A.
    Lee, Stella E.
    Zemke, Anna C.
    Kimple, Adam J.
    INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2022, 12 (02) : 223 - 226
  • [34] Cystic Fibrosis Macrophage Function and Clinical Outcomes After Elexacaftor/Tezacaftor/Ivacaftor Initiation
    Kopp, B. T.
    Zhang, S.
    Shrestha, C.
    Wisniewski, B. L.
    Brown, N.
    Pham, H.
    McCoy, K. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [35] Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis
    Gushue, Courtney
    Eisner, Mariah
    Bai, Shasha
    Johnson, Terri
    Holtzlander, Melissa
    McCoy, Karen
    Sheikh, Shahid
    PEDIATRIC PULMONOLOGY, 2023, 58 (08) : 2308 - 2316
  • [36] Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor
    De Vuyst, Richard
    Kam, Charissa W.
    McKinzie, Cameron J.
    Esther Jr, Charles R.
    PEDIATRIC PULMONOLOGY, 2024, 59 (07) : 2051 - 2054
  • [37] Sustained Improvement of Cystic Fibrosis Lung Disease following Initiation of Elexacaftor/Tezacaftor/Ivacaftor Therapy: Lessons from Real-World Studies
    Steinke, Eva
    Stahl, Mirjam
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (09) : 911 - 913
  • [38] Elexacaftor/Ivacaftor/tezacaftor/Ivacaftor/lumacaftorDrug-induced liver injury
    Reactions Weekly, 2024, 2008 (1) : 142 - 142
  • [39] Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Experiences at a Quaternary CF Care Center
    Papadakis, Lena
    Stander, Tayler
    Mombourquette, Jacqueline
    Richards, Christopher J.
    Yonker, Lael M.
    Lawton, Brenden
    Hardcastle, Margot
    Zweifach, Julia
    Sicilian, Leonard
    Bringhurst, Lindsay
    Neuringer, Isabel P.
    PEDIATRIC PULMONOLOGY, 2025, 60 (01)
  • [40] Improvements in glucose regulation in children and young people with cystic fibrosis related diabetes following initiation of Elexacaftor/Tezacaftor/Ivacaftor
    Park, Julie
    Walsh, Anna
    Kerr, Sue
    Woodland, Clare
    Southward, Suzanne
    Deakin, Mark
    Senniappan, Senthil
    Thursfield, Rebecca
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 (01): : 94 - 98
12345